Breaking News

Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors

Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors

CAMBRIDGE, Mass., May perhaps 18, 2022 /PRNewswire/ — Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical firm centered on strengthening the lives of most cancers people as a result of the discovery, improvement and commercialization of transformative targeted therapies, these days announced the appointment of Don Hayden to its Board of Directors.

“We are thrilled to welcome Don as a huge addition to the Theseus Board. Don is a regarded, deeply experienced leader in the business, and he will bring a distinctive perspective to Theseus as we advance our Period 1/2 medical trial of THE-630 in people with GIST and be expecting to file an IND for our second system in EGFR-driven non-compact cell lung cancer in 2023,” said Tim Clackson, Ph.D., President and Main Government Officer of Theseus. “Don is an field veteran with a document of achievements as an government at big pharmaceutical organizations, as perfectly as board and board chair practical experience at various biopharmaceutical organizations. We are certain to benefit from his awareness and insights as we speed up our scientific portfolio.”

Mr. Hayden has over 40 decades of practical experience in the existence sciences business, possessing served in various strategic leadership positions in the course of his 25-calendar year job at Bristol Myers-Squibb Business (BMS), which include roles as President of Oncology and Immunology and as President of World-wide Prescription drugs. Pursuing BMS, Mr. Hayden has served as Chair at REGENXBIO, Amicus Therapeutics, Insmed, Vitae Prescription drugs, and Gloucester Prescribed drugs, amid other folks, across which he presented strategic guidance by a assortment of corporate milestones, including company combinations, financings, IPOs, and bringing approved therapies to market. A lot more a short while ago, Mr. Hayden served as Chair and CEO of oncology mobile treatment developer, WindMIL Therapeutics. In addition to his new function at Theseus, Mr. Hayden also presently serves as Chair of Otsuka The united states Prescribed drugs Incorporated. He holds an M.B.A from Indiana College and undergraduate degree from Harvard University.

Mr. Hayden added, “Theseus has an excellent management crew, with significant good results in qualified oncology, and demonstrates enormous probable to beat most cancers cure resistance with its pan-variant solution to targeted treatment. I seem ahead to supporting the Firm’s ongoing progress and scientific improvement, as it seeks to translate the electrical power of its unique science into major added benefits for cancer individuals.”

About Theseus Prescribed drugs, Inc.
Theseus is a clinical-stage biopharmaceutical firm focused on strengthening the lives of cancer individuals through the discovery, enhancement and commercialization of transformative specific therapies. Theseus is doing the job to outsmart cancer resistance by acquiring pan-variant tyrosine kinase inhibitors (TKIs) to goal all identified classes of most cancers-producing and resistance mutations that direct to variants in a individual protein in a supplied type of cancer. Theseus’ direct product or service prospect, THE-630, is a pan-variant Kit inhibitor for the procedure of sufferers with state-of-the-art gastrointestinal stromal tumors (GIST), whose cancer has formulated resistance to before strains of kinase inhibitor remedy. Theseus is also producing a fourth-era, selective epidermal expansion variable receptor (EGFR) inhibitor for C797S-mediated resistance to first- or afterwards-line osimertinib cure in patients with non-small mobile lung most cancers (NSCLC). For far more information, take a look at www.theseusrx.com.

Cautionary Assertion With regards to Forward Looking Statements
Selected statements involved in this push launch are not historic details but are ahead-hunting statements for functions of the safe harbor provisions underneath the United States Personal Securities Litigation Reform Act of 1995. Forward-wanting statements commonly are accompanied by words these as “feel,” “might,” “will,” “estimate,” “continue on,” “anticipate,” “intend,” “be expecting,” “must,” “would,” “plan,” “on monitor,” “forecast,” “likely,” “feel,” “search for,” “long term,” “outlook,” and identical expressions that predict or suggest future activities or trends or that are not statements of historic matters, but the absence of these phrases does not suggest that a statement is not ahead-looking. These forward-searching statements contain, but are not restricted to, statements concerning Theseus’ approach, long run operations, prospective clients and plans, the composition and timing of its preclinical scientific tests and clinical trials, anticipated milestones, market place option and sizing and objectives of administration, which includes in relation to the Phase 1/2 dose escalation and growth scientific demo for THE-630, EGFR inhibitor application and other plans and development candidates.

True results may perhaps differ materially from individuals indicated by these types of ahead-hunting statements as a outcome of various crucial things, these types of as those described from time to time in the reports Theseus data files with the Securities and Exchange Fee (SEC), like Theseus’ Sort 10-K for the yr finished December 31, 2021 submitted with the SEC on March 10, 2022 and Theseus’ Sort 10-Q for the quarter finished March 31, 2022 submitted with the SEC on Might 12, 2022. On the other hand, new chance components and uncertainties may emerge from time to time, and it is not doable to predict all hazard things and uncertainties. Accordingly, viewers are cautioned not to position undue reliance on these forward-looking statements. Any ahead-seeking statements contained in this press launch are based on the present anticipations of Theseus’ administration workforce and talk only as of the day hereof, and Theseus especially disclaims any obligation to update any ahead-wanting assertion, no matter whether as a final result of new info, foreseeable future situations or normally, apart from as needed by regulation.

Media Make contact with
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
[email protected]

Investor Get in touch with
Christen Baglaneas
Theseus Prescription drugs
857-706-4993
[email protected]

Josh Rappaport
Stern Trader Relations
212-362-1200
[email protected]

Cision

Look at unique content material:https://www.prnewswire.com/information-releases/theseus-prescription drugs-appoints-don-hayden-to-board-of-administrators-301549652.html

Resource Theseus Pharmaceuticals